Tag: Lotus Edge

Novel repositionable TAVI valve has acceptable early clinical outcomes

A new study indicates that the Meridian transcatheter aortic valve implantation (TAVI) valve (HLT) is associated with a 30-day mortality rate of 8% and...

Lotus Edge becomes third TAVI device on US market

Boston Scientific has received US FDA approval for its Lotus Edge transcatheter aortic valve implantation (TAVI) system. It is approved for patients with severe...

Boston Scientific pushes back plans for commercialisation of Lotus Edge TAVI...

Boston Scientific has announced a delay to the previously communicated timelines for the commercialisation of its Lotus Edge transcatheter aortic valve implantation (TAVI) device...

PCR LV 2017: Refining implantation technique and device iterations may improve...

New data from REPRISE III indicate that keeping the bottom of the frame at annular level while implanting and targeting a final depth of...